Lonza Group Ltd

LONN

Equity

ISIN CH0013841017 / Valor 1384101

SIX Swiss Exchange (2025-12-17)

CHF 523.80+0.92%

Lonza Group Ltd
UMushroom community rating:

4.06 14 votes No rating yet

NegativeNeutralPositive

About company

Lonza Group Ltd is a leading contract development and manufacturing organization (CDMO) that serves the healthcare industry by providing comprehensive services across three main business platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities. The company supports its clients, ranging from emerging biotech firms to large pharmaceutical companies, in transforming therapeutic discoveries into viable treatments. Lonza's offerings cover the entire spectrum from early development to the manufacturing of drug substances and products, utilizing both established and emerging technologies such as mammalian biologics, small molecules, highly potent active pharmaceutical ingredients (APIs), bioconjugates, mRNA, microbial, and cell and gene therapies. In 2024, Lonza reported sales of CHF 6.6 billion and a CORE EBITDA of CHF 1.9 billion. The company is publicly traded on the SIX Swiss Exchange and the Swiss Market Index (SMI), with a secondary listing on the SGX Singapore Exchange. Lonza aims to lead the CDMO industry through innovation, advanced technology, and efficient manufacturing processes.

Summarized from source with an LLMView SourceSector: Industrials

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-3.25%1Y

16.4%3Y

-6.20%5Y

Performance

23.1%1Y

30.3%3Y

29.8%5Y

Volatility